Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EKR to acquire PDL’s cardiovascular assets
Under the terms of the agreement, PDL would receive cash payments of $85 million at closing, up to an additional $85 million in development and sales milestones for
Under the terms of the agreement, PDL would receive cash payments of $85 million at closing, up to an additional $85 million in development and sales milestones for
According to Savient, results were favorable for the treatment effect on clinical outcomes assessed by the reduction in the number of tender and swollen joints, and in improvement
This acquisition is expected to expand Progen’s product candidate portfolio through the addition of multiple preclinical and clinical oncology compounds focused on polyamine and epigenetic targets. Under the
With the support of the Seaside’s funding, Vanderbilt researchers are expected to use medicinal chemistry, molecular biology, pharmacology and efficacy studies to develop compounds that have the properties
The company said that Mr Steinbruchel has been a board member since the company’s inception in 1998. Mr Piwek was president of Overwaitea Foods supermarket from 1991 until
The financing consists of a $13.7 million mortgage with a 16-year term requiring no capital repayments until March 2009, and a $7.4 million loan to finance equipment, repayable
Priority review is granted by the FDA for a treatment that addresses an unmet medical need and demonstrates an improvement over existing therapies. The FDA expedites the approval
The FDA’s action was primarily based on unresolved issues relating to product nomenclature and its belief of a likelihood of medication errors resulting from confusion of Vadova with
Calcitriol injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It significantly reduces elevated levels of parathyroid hormone. Arthur Przybyl, president and CEO
NU172 is an aptamer designed to directly inhibit thrombin’s ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign